Figure 2. Cost variation of HRM analysis for screening of the TP53-p.R337H mutation according to estimated mutation prevalence. (A) Cost comparison of Sanger sequencing, TaqMan-PCR and PCR-RFLP. (B) Expected mutation prevalence scenario.